Bruker winds down underperforming instrument lines


Instrument heavyweight Bruker is winding down its range of stand-alone gas chromatography (GC), inductively-coupled plasma mass spectrometry (ICP-MS) and single quadrupole GC-MS instruments. In a statement, the company said that its Chemical and Applied Markets division, which houses these products, has generated significant losses for the last four years, with little prospect of near-term profitability.

Bruker will honour outstanding orders for the affected GC and GC-MS instruments, but is not taking any new orders. The company is looking to sell off its ICP-MS business, and for someone to take over the service contracts for the GC instruments. The firm will retain support for GC-MS systems, as it continues to sell instruments with triple-quadrupole mass detectors.

At the same time, the company is expanding its microscopy offering in the life sciences, by acquiring US start-up Vutara for its high speed, 3D, super resolution fluorescence microscopy technology. The companies did not disclose financial details of the transaction.


Related Content

X marks the structure

31 October 2014 Review

news image

Elisabeth Jeffries discovers there’s a diffractometer for everything from crystals to proteins

A close look at microscopy

5 November 2013 Review

news image

Elisabeth Jeffries zooms in on scanning probe microscopy and other techniques

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Chemists zinc up ‘aromatic’ metal cubes

2 March 2015 Research

news image

Metal-organic clusters share electrons between eight covalently linked metal atoms

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent